The estimated net worth of Dr. Henry J. Fuchs is at least $78,256,340 as of 5 Mar 2024. He owns shares worth
$12,090,669 as insider, has earned $46,065,671
from insider trading and has received compensation worth at least
$20,100,000 in BioMarin Pharmaceutical Inc..
What is the salary of Henry J. Fuchs?
Dr. Henry J. Fuchs salary is $1,340,000 per year
as Pres of Worldwide R&D in BioMarin Pharmaceutical Inc..
How old is Henry J. Fuchs?
Dr. Henry J. Fuchs is 67 years old, born in 1958.
What stocks does Henry J. Fuchs currently own?
As insider, Dr. Henry J. Fuchs owns shares in one company:
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Dr. Henry J. Fuchs has made 72 insider trades between 2010-2024, according to the Form 4 filled with the SEC. Most recently he sold
35,341 units of BMRN stock worth $3,010,382 on 5 Mar 2024.
The largest trade he's
ever made was exercising 126,389 units of BMRN stock
on 20 Jul 2020. As of 5 Mar 2024
he still owns at least 212,117 units of BMRN stock.
Transaction
Date
Security
Shares
Price per share
Total value
Source
Sale
Common Stock
35,341
$85.18
$3,010,382
Sale
Common Stock
12,000
$90.43
$1,085,112
Option
Common Stock
126,389
$66.24
$8,372,007
Sale
Common Stock
126,389
$130
$16,430,570
Option
Stock Option (Right to buy Common Stock)
49,423
$63.1
$3,118,591
Option
Common Stock
23,011
N/A
N/A
Sale
Common Stock
23,011
N/A
N/A
Option
Stock Option (Right to buy Common Stock)
23,011
$21.03
$483,990
Option
Stock Option (Right to buy Common Stock)
23,011
$66.24
$1,524,249
Sale
Common Stock
20,000
$96.5
$1,930,040
Sale
Common Stock
17,213
$90
$1,549,170
Sale
Common Stock
5,932
$87.86
$521,186
Sale
Common Stock
9,597
$94.09
$902,982
Sale
Common Stock
2,196
$95
$208,620
Sale
Common Stock
12,500
$100
$1,250,000
Sale
Common Stock
12,500
$100
$1,250,000
Sale
Common Stock
2,000
$21.51
$43,020
Option
Stock Option (Right to buy Common Stock)
2,000
$21.51
$43,020
Option
Common Stock
31,000
$76.3
$2,365,393
Sale
Common Stock
3,350
$26.49
$88,742
Option
Stock Option (Right to buy Common Stock)
10,000
$53.31
$533,050
Option
Common Stock
10,000
$53.31
$533,050
Sale
Common Stock
15,000
$89.23
$1,338,405
Option
Common Stock
15,000
$31.98
$479,625
Option
Stock Option (right to buy Common Stock)
15,000
$31.98
$479,625
Option
Common Stock
15,000
$31.98
$479,625
Option
Stock Option (right to buy) Common Stock
15,000
$31.98
$479,625
Sale
Common Stock
15,000
$90.5
$1,357,500
Sale
Common Stock
603
$90
$54,270
Option
Common Stock
603
$90
$54,270
Option
Stock Option (right to buy) Common Stock
603
$90
$54,270
Option
Stock Option (right to buy) Common Stock
14,397
$58.25
$838,553
Sale
Common Stock
14,397
$58.25
$838,553
Option
Common Stock
14,397
$58.25
$838,553
Option
Common Stock
15,000
$26.49
$397,350
Option
Stock Option (Right to buy Common Stock)
15,000
$26.49
$397,350
Sale
Common Stock
15,000
$26.49
$397,350
Sale
Common Stock
15,000
$26.49
$397,350
Option
Common Stock
15,000
$26.49
$397,350
Option
Stock Option (Right to buy Common Stock)
15,000
$26.49
$397,350
Option
Common Stock
15,000
$26.49
$397,350
Option
Common Stock (Right to buy Common Stock)
15,000
$26.49
$397,350
Sale
Common Stock
15,000
$26.49
$397,350
Option
Common Stock (Right to buy Common Stock)
15,000
$26.49
$397,350
Sale
Common Stock
15,000
$87.69
$1,315,350
Option
Common Stock
15,000
$26.49
$397,350
Sale
Common Stock
1,864
$122.32
$228,001
Sale
Common Stock
1,864
$124.78
$232,584
Sale
Common Stock
1,434
$121.37
$174,037
Sale
Common Stock
2,869
$121.64
$348,988
Sale
Common Stock
414
$114.59
$47,442
Option
Stock Option (right to buy) Common Stock
40,000
$21.51
$860,400
Option
Common Stock
40,000
$21.51
$860,400
Sale
Common Stock
41,315
$123.57
$5,105,171
Sale
Common Stock
20,000
$21.51
$430,200
Option
Common Stock
20,000
$21.51
$430,200
Option
Stock Option (right to buy) Common Stock
20,000
$21.51
$430,200
Sale
Common Stock
10,000
$21.51
$215,100
Option
Common Stock
10,000
$21.51
$215,100
Option
Stock Option (right to buy) Common Stock
10,000
$21.51
$215,100
Sale
Common Stock
1,864
$56.86
$105,994
Sale
Common Stock
2,868
$58.23
$166,995
Sale
Common Stock
3,479
$57.91
$201,476
Sale
Common Stock
715
$59.67
$42,666
Option
Stock Option (right to buy) Common Stock
10,000
$21.51
$215,100
Sale
Common Stock
10,000
$21.51
$215,100
Option
Common Stock
10,000
$21.51
$215,100
Sale
Common Stock
916
$68.97
$63,172
Option
Common Stock
10,000
$11.05
$110,500
Sale
Common Stock
10,000
$11.05
$110,500
Sale
Common Stock
10,000
$11.05
$110,500
Option
Common Stock
10,000
$11.05
$110,500
Option
Common Stock
10,000
$11.05
$110,500
Sale
Common Stock
10,000
$11.05
$110,500
Sale
Common Stock
1,098
$58.32
$64,036
Sale
Common Stock
8,710
$67.16
$584,981
Option
Common Stock
10,000
$11.05
$110,500
Sale
Common Stock
11,899
$65.66
$781,241
Option
Common Stock
20,000
$11.05
$221,000
Sale
Common Stock
20,000
$11.05
$221,000
Option
Stock Option (right to buy)
20,000
$11.05
$221,000
Option
Common Stock
10,000
$11.05
$110,500
Sale
Common Stock
10,000
$11.05
$110,500
Option
Stock Option (right to buy)
10,000
$11.05
$110,500
Sale
Common Stock
5,000
$11.05
$55,250
Option
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Sale
Common Stock
5,000
$11.05
$55,250
Option
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Sale
Common Stock
5,000
$11.05
$55,250
Option
Common Stock
5,000
$11.05
$55,250
Sale
Common Stock
5,000
$11.05
$55,250
Option
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
15,000
$11.05
$165,750
Option
Common Stock
15,000
$11.05
$165,750
Sale
Common Stock
15,000
$40.28
$604,215
Option
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Sale
Common Stock
5,000
$11.05
$55,250
Sale
Common Stock
1,741
$38.64
$67,279
Option
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy
5,000
$11.05
$55,250
Sale
Common Stock
5,000
$11.05
$55,250
Sale
Common Stock
7,691
$35
$269,185
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Sale
Common Stock
5,000
$11.05
$55,250
Option
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
2,500
$11.05
$27,625
Option
Common Stock
2,500
$11.05
$27,625
Sale
Common Stock
2,500
$11.05
$27,625
Sale
Common Stock
2,500
$11.05
$27,625
Option
Stock Option (right to buy)
2,500
$11.05
$27,625
Option
Common Stock
2,500
$11.05
$27,625
Sale
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Option
Common Stock
5,000
$11.05
$55,250
Sale
Common Stock
2,500
$11.05
$27,625
Option
Common Stock
2,500
$11.05
$27,625
Option
Stock Option (right to buy)
2,500
$11.05
$27,625
Option
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Sale
Common Stock
13,165
$19.03
$250,464
Sale
Common Stock
2,500
$11.05
$27,625
Option
Stock Option (right to buy)
2,500
$11.05
$27,625
Option
Common Stock
2,500
$11.05
$27,625
Option
Stock Option (right to buy)
834
$11.05
$9,216
Option
Common Stock
834
$11.05
$9,216
Sale
Common Stock
834
$11.05
$9,216
Option
Stock Option (right to buy)
833
$11.05
$9,205
Sale
Common Stock
833
$11.05
$9,205
Option
Common Stock
833
$11.05
$9,205
Option
Common Stock
833
$11.05
$9,205
Option
Stock Option (right to buy)
833
$11.05
$9,205
Sale
Common Stock
833
$11.05
$9,205
Option
Common Stock
5,000
$11.05
$55,250
Sale
Common Stock
5,000
$11.05
$55,250
Option
Stock Option (right to buy)
5,000
$11.05
$55,250
Option
Common Stock
834
$11.05
$9,216
Option
Stock Option (right to buy)
834
$11.05
$9,216
Sale
Common Stock
834
$11.05
$9,216
Option
Common Stock
833
$11.05
$9,205
Sale
Common Stock
2,435
$18.4
$44,809
Option
Stock Option (right to buy)
833
$11.05
$9,205
Option
Stock Option (right to buy)
833
$11.05
$9,205
Sale
Common Stock
833
$11.05
$9,205
Option
Common Stock
833
$11.05
$9,205
Option
Common Stock
834
$11.05
$9,216
Option
Stock Option (right to buy)
834
$11.05
$9,216
Sale
Common Stock
834
$11.05
$9,216
Sale
Commn Stock
833
$11.05
$9,205
Option
Common Stock
833
$11.05
$9,205
Option
Stock Option (right to buy)
833
$11.05
$9,205
Option
Stock Option (right to buy)
833
$11.05
$9,205
Option
Common Stock
833
$11.05
$9,205
Sale
Common Stock
833
$11.05
$9,205
Option
Stock Option (right to buy)
834
$11.05
$9,216
Sale
Common Stock
834
$11.05
$9,216
Option
Common Stock
834
$11.05
$9,216
Option
Stock Option (right to buy)
833
$11.05
$9,205
Option
Common Stock
833
$11.05
$9,205
Sale
Common Stock
2,275
$16.92
$38,493
Sale
Common Stock
5,833
$11.05
$64,455
Option
Common Stock
5,833
$11.05
$64,455
Option
Stock Option (right to buy)
5,833
$11.05
$64,455
BioMarin Pharmaceutical key executives
BioMarin Pharmaceutical Inc. executives and other stock owners filed with the SEC:
Dr. C. Greg Guyer Ph.D.(63)Chief Technology Officer and Executive Vice President of Global Manufacturing & Technical Operations
